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The replication of human immunodeficiency virus in vitro is inhibited by some acyclic adenosine derivatives,
such as 9-(2-phosphonylmethoxyethyl)adenine (PMEA) and (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)-
2,6-diaminopurine [(S)-HPMPDAPJ, as well as by 3'-azido-3'-deoxythymidine (AZT). In a human T-
lymphocyte cell line, C3, at 6 days postinfection, the 50% effective concentration (EC50) of AZT was 0.02 ,IM
and the 90% effective concentration (EC90) was 0.33 ,uM; for PMEA, the EC50 was 1.9 ,uM and the EC90 was
27 ,uM. For (S)-HPMPDAP, the EC50 was 2.3 ,uM and the EC%0 was 36 ,uM. Most combinations of AZT and
PMEA produced a synergistic effect. In the T-cell line C3, the combination indices for 50 to 90% inhibition of
virus replication ranged from 0.25 to 1.25. Combinations of PMEA (or other members of this group) with AZT
appear to be worth further study for the possible treatment of acquired immunodeficiency syndrome.
The search for effective therapy for acquired immunode-
ficiency syndrome (AIDS) has uncovered various classes of
compounds which show activity in vitro against human
immunodeficiency virus type 1 (HIV-1), the causative agent.
Among these are suramin (18), nucleoside analogs (17, 19),
pyrophosphate analogs (28), ribavirin (16), alpha interferon
(10), sulfated polysaccharides (11, 23), inhibitors of glyco-
protein processing (9, 30), CD4-binding competitors (8),
antisense or other oligonucleotides (15, 20, 33), and glycyr-
rhizin (12). Among the nucleoside analogs, a new class,
phosphonylmethoxyalkylpurine and pyrimidine derivatives,
has shown activity against herpesviruses and other DNA
viruses (5, 6, 14), as well as in vitro activity against trans-
formation of murine embryo fibroblasts by the Moloney
murine sarcoma virus and against HIV infection ofMT4 cells
(25).
Clinical trials with 3'-azido-3'-deoxythymidine (AZT) in
patients with AIDS show beneficial results in some clinical
parameters and in decreasing or delaying mortality (7);
however, AZT toxicity develops in a sizable portion of the
treated population (27). Combinations of drugs which would
result in an equivalent antiviral effect while reducing overall
toxicity would be of great value. We confirm here that some
of the acyclic adenosine derivatives inhibit HIV, and we
demonstrate that the combination of 9-(2-phosphonyl-
methoxyethyl) adenine (PMEA) with AZT results in a syn-
ergistic effect.
(Preliminary results of parts of this work were presented at
the Second International Conference on Antiviral Research,
10 to 14 April 1988, Williamsburg, Va.)
MATERIALS AND METHODS
Virus and cells. The LAV strain of HIV was obtained from
L. Montagnier, and stocks were prepared in H9 or C3 cells.
The human T-cell line H9 was grown in RPMI 1640 with 8%
fetal calf serum. C3, a human T-lymphocyte line harboring
latent human T-cell lymphotropic virus type 11 (26) obtained
* Corresponding author.
from William M. Mitchell, was grown in the same medium.
Cells were infected for drug experiments with 600 50% tissue
culture infective doses of the LAV strain in the presence of
2 ,ug of DEAE-dextran per ml for 1 h and then washed twice
in medium to remove excess virus. After this washing,
aliquots of 5 x 10' cells were set up in the presence or
absence of drugs in 48-well plates. For C3 cells, samples of
supernatant medium were taken at day 6 or 7, when the
positive control was at its peak. H9 cultures in drug exper-
iments were sampled on day 6 or 7.
Test compounds. The phosphonylmethoxyalkylpurines
and pyrimidines were obtained from A. Holy and I. Rosen-
berg, from the Institute of Organic Chemistry and Bio-
chemistry, Czechoslovak Academy of Sciences, Prague,
Czechoslovakia. The structures are shown in Fig. 1. The





methoxypropyl)cytosine [(S)-HPMPC], cyclic phosphonate
of (S)-HPMPA [(S)-cHPMPA], and 9-(2-phosphonylmeth-
oxyethyl)-2,6,diaminopurine (PMEDAP). 3'-Azido-3'-de-
oxythymidine (AZT) was kindly provided by S. Lehrman
Nusinoff of Burroughs Wellcome Co., Research Triangle
Park, N.C.
Drug toxicity. Cell viability was determined by exclusion
of trypan blue dye. For growth curves, several aliquots of
cells were set up on day 0 in multiwell plates in each different
drug concentration and counted daily by Coulter counter on
days 1 through 4, the time during which the cells were in
logarithmic growth.
RT assay. Virus-associated reverse transcriptase (RT)
activity was assayed in duplicate 50-,ul reactions containing
30 ,u of clarified unconcentrated supernatant medium and 5
,uCi of [3H]dTTP (specific activity, 60 to 80 Ci/mmol; Amer-
sham Corp.) with the addition (final concentrations) of 10
mM Tris hydrochloride (pH 7.5), 8 mM MgCl2, 10 mM
dithiothreitol, 0.5% Triton X-100, 50 jig of poly(A) per ml,
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FIG. 1. Structures of the acyclic adenosine derivatives.
and 10 p.g of oligo(dT)12_18 (Pharmacia, Inc.) per mnl. After
incubation at 37°C for 45 min, 40 of each duplicate
reaction was spotted onto DE81 paper (Whatman, Inc.),
washed, and counted as described previously (29).
Synergy calculations. The multiple drug effect analysis of
Chou and Talalay (2) was used to calculate combined drug
effects with the use of computer software (1). Combination
indices were calculated on the basis of both mutually non-
exclusive and mutually exclusive effect equations by the
following equation:
Xcombo Ycombo (Xcombo Ycombo)CI=~ + ~~+
Xalone Yalone Xalone * Yalone
where at is 0 for the mutually exclusive drug effect and 1 for
the mutually nonexclusive drug effect, Xalone is the concen-
tration of drug X which gives a certain percentage of RT
inhibition, and Xcombo is the concentration of drug X which,
in combination with drug Y, gives a certain percentage ofRT
inhibition. CI values of <1 indicate synergy, CI values of >1
indicate antagonism, and a CI value of 1 indicates the
additive effect of the two drugs. The classical isobologram
for 90% effective concentration (EC90) levels was also used
to depict synergism of combined drug effects. For this graph,
the concentration of one drug giving the desired effect (e.g.,
90% reduction of virus production) is plotted on one axis and
the concentration of the other drug giving the same percent-
age reduction is plotted on the other axis. A line is drawn
between these two points; the concentrations of combina-
tions of the two drugs giving the same percentage effect are
also plotted. If these points fall under the line, the combina-
tion is considered synergistic for mutually exclusive drugs; if
they fall above the line, they are considered antagonistic;
and if they are on the line, they are considered additive.
TABLE 1. Effect of acyclic adenosine congeners on HIV
replication and growth of human T-cell lines
C3 EC50 C3 EC90 H9 EC90 C3 IC50 H9 IC50 C3 1C50/Drug (>M)" (p.M)b (,M) (p.M)C (,uM)(CM)
PMEA 1.9 27 8 >200 51 >100
(S)-HPMPDAP 2.3 36 64 >200 >100 >83
PMEDAP 0.2 3 0.1 >200 17 >1,000
AZT 0.02 0.33 0.3 10 30 500
AZT:PMEA 0.24 NDe ND >51 ND >212
(1:50)d
"EC50 is the concentration which decreased the RT level by 50% compared
with that in the control infection.
b ECg is the concentration which decreased the RT level by 90% compared
with that in the control infection.
' IC50 is the concentration which decreased the total cell number by 50%
after 4 days in the drug.




Effect of acyclic adenosine derivatives on HIV replication.
Six acyclic adenosine derivatives were tested for the ability
to inhibit HIV replication in cultures of human T-cell lines
(H9 or C3). The drug, (S)-HPMPA, reported to inhibit
transformation of mouse embryo fibroblasts by Moloney
murine sarcoma virus (5), did not inhibit HIV replication at
nontoxic doses (data not shown). The other drugs all showed
some effect in H9 and C3 cells at levels of drug not causing
significant reduction in cellular growth rate. The levels of
drug capable of causing a 50 or 90% reduction in RT level
(EC5( and EC90) are shown in Table 1. Dose-response curves
for AZT were performed for comparison. PMEA and (S)-
HPMPDAP showed similar activity in C3 cells, whereas the
PMEDAP produced an EC90 at a 10-fold-lower concentra-
tion in C3 cells and was almost as effective as AZT on a
molar basis in H9 cells.
Growth inhibition by acyclic adenosine derivatives. Growth
rates of uninfected cells (C3 and H9) in the presence of
various concentrations of PMEA, (S)-HPMPDAP, and
PMEDAP were determined. The concentrations resulting in
50% reduction in total cell number on day 5 are shown in
Table 1. After 4 days of exposure to drug, H9 cell viabilities
remained above 90% with levels of PMEA and (S)-HPMP-
DAP below 10 ,uM, and H9 cell viabilities dropped to 86 and
60% in 100 puM levels of the two drugs, respectively. For the
synergy experiments, the toxicity of the combined drugs
AZT and PMEA was tested on the uninfected C3 cell line.
The combination of 1 p.M AZT plus 10 p.M PMEA resulted
in 90% viable cells after 4 days in the presence of drug. Thus,
at effective antiviral levels, PMEA and (S)-HPMPDAP had
only a slightly cytostatic effect which did not increase in the
combination of PMEA with a low concentration of AZT.
Combination of AZT and PMEA. Various combinations of
low levels of AZT and PMEA as well as each drug alone
were added to C3 cells immediately after infection and
removal of excess virus in two separate experiments. The
virus production was determined by RT assay at day 6 or 7.
Virus production in the presence of each combination is
shown in Fig. 2, where it can be seen, for example, that the
effect of 0.01 p.M AZT plus 0.1 p.M PMEA (virus production
at 60% of control infection) was greater than that of 0.01 pM
AZT alone (76% of control) or of 0.1 p.M PMEA alone (88%
of control). The fitting of the data for AZT alone and for
PMEA alone to the median-effect plot (log FaIFu versus log
0
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FIG. 2. Effect of combinations of PMEA and AZT on HIV
replication in C3 cells. Virus production was determined by RT
assay, shown here as percent of the positive control culture. AZT
concentrations: *, 0; El, 0.002 ,uM; X, 0.01 ,uM; O, 0.05 R1M; E,
0.1 AM. umolar, Micromolar.
concentration, where Fa is the fraction affected, or 1 -
percent inhibition, and F,4 is the fraction unaffected, or 1 -
Fa) resulted in linear correlation coefficients (r) of 0.995 and
0.992, respectively. The measure of virus production was
analyzed for synergy of the two compounds by applying the
multiple drug effect analysis to the RT data. Synergy calcu-
lations were performed for all datum points resulting in less
than 99% inhibition by combination indices (Table 2) and by
a classical isobologram derived from the data in Fig. 2 (Fig.
3). Both methods are derived from the same set of equations,
and both indicated synergism between these drugs. As seen
in Table 2, a few of the combinations give rise to combina-
tion indices of >1; these may be due to experimental
variation, as they are the same points that appear to deviate
from a perfect progression of inhibition in Fig. 2. As shown
in Table 2, all combinations (eight of eight datum points) of
AZT and PMEA producing in excess of 68.1% inhibition
showed synergistic inhibitory effects on HIV-1 replication in











TABLE 2. Combination indices for treatments with AZT
and PMEA on RT in C3 cells
Combination











0.002 0.1 1:50 0.102 0.236 0.63 0.72
0.002 1 1:500 1.002 0.415 1.25 1.36
0.002 5 1:2500 5.002 0.681 1.24 1.27
0.002 10 1:5000 10.002 0.833 0.74 0.75
0.01 0.1 1:10 0.11 0.403 0.60 0.66
0.01 1 1:100 1.01 0.738 0.25 0.26
0.01 10 1:1000 10.01 0.813 0.94 0.98
0.05 0.1 1:2 0.15 0.613 0.86 0.89
0.05 1 1:20 1.05 0.638 1.04 1.27
0.05 5 1:100 5.05 0.898 0.26 0.28
0.1 0.1 1:1 0.2 0.785 0.60 0.60
0.1 1 1:10 1.1 0.810 0.57 0.62
0.1 5 1:50 5.1 0.878 0.47 0.53
0.1 10 1:100 10.1 0.897 0.53 0.60
" Molar ratio of AZT and PMEA in the mixture.
b Sum of the concentrations of AZT and PMEA.
' Fraction affected for RT is calculated as [1 - (RT of drug-treated culture
- background/RT of no-drug culture - background)].
d Combination indices are calculated as described in references 1 and 2; the
values shown are for the mutually exclusive drug effect (ot = 0) and for
mutually nonexclusive effect (a = 1).
inhibition, three of six datum points showed synergism and
the other three datum points showed antagonism. This trend
of svner2ism is favorable since in actual theranv one would
expect the inhibitory effect shown to be 90% or more. The
equipotency ratio based on EC50s for AZT (0.02 ,uM) and
PMEA (1.9 ,uM) is 1:95 (Table 1). The combinations empha-
sizing AZT effect (or concentration) or de-emphasizing
PMEA effect around this ratio tend to favor synergism,
whereas the combinations de-emphasizing AZT effect or
emphasizing PMEA effect tend to yield additive or antago-
nistic effects (Table 2). Also, AZT and PMEA effects,
whether they are mutually exclusive (a = 0) or mutually
nonexclusive (a = 1), yield similar combination indices and
thus similar degrees of synergism or antagonism (Table 2).
Lack of effect of PMEA on in vitro RT activity. PMEA was
tested in in vitro RT assays to verify that residual drug (a
nucleoside monophosphate analog) from supernatant me-
dium would not directly inhibit the RT activity being used as
a measure of virus production in the drug experiments. Final
concentrations of PMEA ranging from 0.1 to 50 ,uM were
24 32 included in the RT assay of a high-titer stock and resulted in
no decrease in incorporated [3H]dTTP (data not shown).
FIG. 3. Isobologram for ED90 level of PMEA and AZT. Individ-
ual points represent the concentrations of a combination of the two
drugs giving the same degree of inhibition (90%) of virus production,
based on the data in Fig. 2. UM, Micromolar.
DISCUSSION
The biochemical mechanism by which PMEA and its
congeners achieve their antiviral effect against HIV replica-
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tion remains the subject of further study. These drugs were
designed with the phosphorus atom attached via a P-C bond,
such that hydrolysis by phosphomonoesterases could be
prevented. One of these drugs, (S)-HPMPA, it taken up by
cells and subsequently phosphorylated to its mono- and
diphosphoryl derivatives, presumably by cellular nucleotide
kinases (32). The ether linkage between the alkyl residue and
the phosphonylmethyl group cannot be metabolized to
phosphonoacetate (PAA) or to phosphonoformate, which is
known to inhibit HIV (28); this lack of metabolism is further
documented by the activity of (S)-HPMPA against two DNA
polymerase PAAr mutants of HSV-1 (5). In addition, only
the (S)-enantiomer has antiviral activity; thus, the antiviral
effect is based on its chirality. Also, the drugs are not
thought to interact with S-adenosylhomocysteine hydrolase
(5), nor are they degraded by deaminases (25).
In addition to inhibiting several DNA viruses (4, 5, 14, 32),
these drugs (i.e., PMEA and PMEDAP) have been shown
recently to inhibit HIV-induced cytopathology and antigen
expression in MT-4, ATH8, and H9 T-lymphocyte cells in
vitro, as well as inhibiting transformation of mouse fibro-
blasts by Moloney murine sarcoma virus (25). Our results for
the 50% inhibitory concentration (IC50) and EC50 of PMEA
and PMEDAP agree well with those published by Pauwels et
al. (25), despite the differences in the systems used; Pauwels
et al. assessed the 50% effective dose (ED50) by cytopathic
effect and immunofluorescence in H9 and MT4 cells,
whereas we have monitored virus production by RT assay in
C3 and H9 cells. Recently, the toxicity and prophylactic
antiviral activity of PMEA was tested in the feline retrovirus
system (L. E. Mathes, C. L. Swenson, P. A. Polas, R. Sams,
K. Hayes, and G. Kociba, Abstr. 5th Int. Conf. AIDS, abstr.
no. MCP69, p. 553, 1989). At a dosage of 12.5 mg/kg per day,
and a level in plasma of 1 to 2 ,ug/ml (approximately 5 ,uM),
3 weeks of infusion prevented or delayed the onset of
infection in six of six challenged animals, whereas seven of
seven control cats developed chronic viremia by 3 weeks
postchallenge.
Another combination of nucleosides (ribavirin and AZT)
has produced a decrease in the level of AZT triphosphate in
cells, resulting in an antagonistic effect (31; J. A. Fyfe, P.
Furman, M. Vogt, and P. Sherman, Abstr. 4th Int. Conf.
AIDS, abstr. no. 3617, book 2, p. 170, 1988). We do not
believe that PMEA is decreasing dTTP pools in the treated
cells. PMEA (at levels up to 500 puM) does not affect the
incorporation of [methyl-3H]deoxythymidine into DNA in
MT-4 cells (J. Balzarini and E. De Clercq, unpublished
results). We can infer that the dTMP, dTDP, and dTTP
levels are probably not decreased, since [methyl-3HJde-
oxythymidine has to go through these steps in order to be
incorporated into DNA, although inhibition of de novo
derived pools of dTMP, dTDP, and dTTP is not ruled out. In
addition, the anti-HIV activity of PMEA in MT-4 cells was
not reversed upon the addition of 200 ViM adenosine, 200 VLM
2'-deoxyadenosine, 200 FM cytidine, 200 ,uM 2'-deoxycyti-
dine, 25 ,uM thymidine, or 2 pFM guanosine, suggesting that
altered nucleotide pools are not responsible for the antiviral
effect.
Treatment of AIDS patients with AZT alone has resulted
in side effects such as anemia and neutropenia; some pa-
tients are forced to reduce the dosage or discontinue its use
altogether (27). AZT alone (most probably like most nucle-
oside analogs) is unable to stop production of virus from
already infected lymphocytes in vitro (24) or to completely
prevent new infection of susceptible lymphocytes in vitro
(29). The combination of AZT, a thymidine analog, with an
acyclic adenosine analog may allow an effective antiviral
dosage of the combination while still using a low dose of
AZT, perhaps alleviating the side effects of both drugs. Bone
marrow toxicity was observed in cats with PMEA at 12.5
mg/kg per day; lower dosages are currently being tested for
toxicity and prophylactic activity (Mathes et al., Abstr. 5th
Int. Conf. AIDS, 1989). Another possible clinical advantage
may be that these drugs are active in vitro against several
human herpesviruses, including herpes simplex virus types 1
and 2, varicella-zoster virus, cytomegalovirus, and Epstein-
Barr virus, all of which are prevalent in acquired immuno-
deficiency syndrome and all of which may affect HIV
transcription (3, 13, 21). If these drugs prove to be well
tolerated in vivo, they may show an additional indirect
benefit because of their broad activity against these other
viruses (22).
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